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Alcohol consumption is considered a major risk factor for disease and mortality 
worldwide. In the absence of effective treatments in alcohol use disorders 
(AUD) it is important to find new biological targets that could modulate alcohol 
consumption. We tested the role of the N-terminal Galanin fragment (1-15) 
[GAL(1-15)] in voluntary ethanol consumption in rats using the two-bottle choice 
paradigm as well as compare the effects of GAL(1-15) with the whole molecule 
of Galanin (GAL). We describe for the first time that GAL(1-15), via central 
mechanisms, induces a strong reduction in preference and ethanol 
consumption in rats. These effects were significantly different than GAL. 
Galanin receptor (GALR) 2 was involved in these effects, since the specific 
GALR2 antagonist M871 blocked GAL(1-15) mediated actions in preference 
and ethanol intake. Importantly, the mechanism of this action involves changes 
in GALR expression and also in immediate-early gene C-Fos and receptors-
internalization-related gene Rab5 in the striatum. The relevance of the striatum 
as a target for GAL(1-15) was supported by the effect of GAL(1-15) on the 
locomotor activity of rats after ethanol administration. These results may give 
the basis for the development of novel therapeutics strategies using GAL(1-15) 
analogues for the treatment of AUD in humans. 
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INTRODUCTION  
Alcohol consumption is considered a major risk factor for disease and mortality 
worldwide according to the World Health Organization (2014). Current therapies 
in alcohol use disorders (AUD) have limited efficacy, produce several adverse 
effects and present high rates of relapse. In the absence of effective treatments 
it is therefore of great importance to find new biological targets that could 
modulate alcohol consumption. Numerous neurotransmitters have been 
implicated in AUD including GABA, glutamate, dopamine, noradrenaline, 
serotonin and several endogenous neuropeptides (Schneider et al., 2007; 
Marcinkiewcz et al., 2016).  
Galanin (GAL) is a neuropeptide (Tatemoto et al., 1983) widely distributed in 
neurons within the central nervous system (CNS) (Jacobowitz et al., 2004). 
Three GAL receptor (GALR1-3) subtypes with high affinities for GAL have been 
cloned (Branchek et al., 2000; Mitsukawa et al., 2008). GALR1 and GALR3 
mainly activate inhibitory G proteins Gi/Go, while GALR2 mainly couples to 
Gq/G11 to mediate excitatory signalling (Branchek et al., 2000). 
GAL participates in a number of central functions modulating neuroendocrine 
levels, pain control, cardiovascular functions, food intake and mood disorders 
(Mitsukawa et al., 2008; Diaz-Cabiale et al., 2010; Lang et al., 2015). GAL and 
their receptors are also involved in drug abuse and addiction (Picciotto, 2008), 
including alcohol intake and alcoholism (Lewis et al., 2004; Lewis et al., 2005). 
Microinjection of GAL into the third ventricle increased ethanol consumption in 
Sprage-Dawley rats in two-bottle choice test from a 7% ethanol solution over 
water, and this increase was completely reversed with the GAL receptor 
antagonist M40 (Lewis et al., 2004). These effects of GAL over ethanol 
consumption were also found with microinjections of GAL directly into the 
paraventricular nucleus (PVN) of the hypothalamus (Rada et al., 2004). 
Moreover, mice overexpressing GAL show an increase in preference and 
ethanol intake in comparison with their wild-type peers (Karatayev et al., 2009), 
while GAL knockout mice drink less ethanol and decrease the preference for it 
(Karatayev et al., 2010). Not only the PVN but also the reward circuitry seems 
to be involved in the effects of GAL promoting alcohol drinking. Injection of GAL 
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in the PVN can increase dopamine release in the nucleus accumbens (NAc) 
(Rada et al., 1998), and this effect would be consistent with the ability of GAL to 
increase the rewarding effects of alcohol (Picciotto et al., 2010). 
In addition to GAL, also the N-terminal fragments like GAL(1-15) are active in 
the CNS (Hedlund et al., 1996; Diaz-Cabiale et al., 2005; Diaz-Cabiale et al., 
2010; Millon et al., 2015; Millon et al., 2016; Flores-Burgess et al., 2017; Millon 
et al., 2017). Both GAL and GAL(1-15) molecules have specific roles in 
cardiovascular regulation and interact differently with other neuropeptides (Diaz-
Cabiale et al., 2005). Recently we have described that GAL(1-15) induces a 
strong depression-related and anxiogenic-like effects in rats and these effects 
were significantly stronger than the ones induced by GAL. The GALR1/GALR2 
heteroreceptor complexes in the dorsal hippocampus and especially in the 
dorsal raphe, areas rich in GAL(1-15) binding sites (Hedlund et al., 1992), were 
involved in these effects (Millon et al., 2015). The presence of specific binding 
sites for GAL(1-15) in the dorsal hippocampus, neocortex and striatum 
(Hedlund et al., 1992), which is part of mesolimbic dopamine system (Koob, 
1992), suggest a role of GAL(1-15) in the circuits related to the rewarding and 
motivational effects of drugs of abuse.  
The purpose of the current study was to assess the role of 
intracerebroventricular (i.c.v.) GAL(1-15) in voluntary ethanol consumption in 
rats using the two-bottle choice paradigm as well as compare the effects of 
GAL(1-15) with the GAL. Moreover, the involvement of GALR2 in GAL(1-15)-
mediated effects in this test was analysed with the selective GALR2 antagonist 
M871. In order to investigate whether the effect of GAL(1-15) in voluntary 
ethanol consumption was associated with the reward-circuit, we have studied in 
the striatum the effect of GAL(1-15) in the expression of the immediate-early 
gene C-Fos, the receptors-internalization related gene Rab5 and the GALR1 
and GALR2. We therefore investigated the effects of GAL(1-15) treatment on 
the locomotor activity induced by alcohol. 
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MATERIAL AND METHODS 
Animals 
Male Sprague Dawley rats (body weight 225–250g, age 8 weeks) were 
obtained from Criffa and maintained in a humidity- and temperature-controlled 
(20–22oC) room. The rats in the two-bottle choice paradigm were during the 
entire protocol maintained on a 12-hour reversed light/dark cycle (lights off at 10 
am) whereas the other rats kept on 12- /hour light/dark cycle. The animals had 
free access to food pellets and tap water. All animal experimentation was 
conducted in accordance with the University of Málaga Guidelines for the Care 
and Use of Laboratory Animals. 
 
Intracerebroventricular Injections 
This protocol has been used previously (Diaz-Cabiale et al., 2011; Millon et al., 
2015). Briefly, the rats were anesthetized intraperitoneally with Equitesin (21.3g 
choral hydrate, 10.6g magnesium sulphate and 4.8g phenobarbitone dissolved 
in 500mL destilated water containing 9.5% ethanol and propylene 
glycol ;3.3mL/kg body weight), and stereotaxically implanted with a unilateral 
chronic 22-gauge stainless-steel guide cannula into the right lateral cerebral 
ventricle using the following coordinates: 1.4mm lateral and 1mm posterior to 
bregma, and 3.6mm below the surface of the skull (Paxinos, 1986). After 
surgery, animals were individually housed and allowed a recovery period of 7 
days. The injections in the lateral ventricle were performed using a 26-gauge 
stain less-steel injection cannula connected via a PE-10 tubing to a Hamilton 
syringe. The total volume was 5 μl per injection and the infusion time was 1min. 
Solutions were prepared freshly and the peptides were dissolved in artificial 
cerebrospinal fluid (composition is 120nM NaCl, 20nM NaH2CO3, 2nM KCl, 
0.5nM KH2PO4, 1.2nM CaCl2, 1.8 nM MgCl2, 0.5 nM Na2SO4, and 5.8 nM D-
glucose, pH 7.4). GAL was obtained from NeoMPS, Strasbourg, France; 
GAL(1–15) and the GALR2 receptor antagonist M871 were obtained from 
Tocris Bioscience,Bristol,UK. 
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Two-bottle choice test for voluntary ethanol consumption and preference 
The two-bottle choice test was used to determine the voluntary ethanol 
consumption of rats as described previously (Castilla-Ortega et al., 2016). 
Briefly, after 7 days of water consumption (both bottles), a choice between 
water and increasing ethanol concentration [3, 6 and 10% (v/v)] was offered for 
7 days each. A choice between 10% (v/v) ethanol and water was offered for 
several days until reaching a stable baseline. Water and ethanol consumption 
were recorded daily. The bottles positions were changed every day to avoid 
position preferences. Water intake (g/Kg), ethanol intake (g/Kg) and preference 
[ethanol consumption/total fluid (water plus ethanol) consumption x100] were 
calculated for each animal. Throughout the experiment, evaporation/spillage 
estimates were calculated using an empty cage with two bottles, one containing 
water and the other containing the appropriate ethanol solution. In the 
experiments a choice between ethanol (10%) and water was offered. 
Three sets of experiments were conducted in the two-bottle choice paradigm. In 
the first set of experiments, a dose-response curve of GAL(1-15) was performed. 
For this, groups of rats received i.c.v. GAL(1-15) 1 nmol, 3 nmol or vehicle 2, 14 
and 24 hours before the measures. In the second set of experiments, the 
effects in two-bottle choice test of GAL and GAL(1-15) were compared. For this, 
groups of rats received i.c.v. GAL 3 nmol, GAL(1-15) 3 nmol or vehicle 2, 14 
and 24 hours before the test. In the last set of experiments, the role of the 
GALR2 was studied; for this groups of rats received i.c.v. GAL(1-15) 3nmol 
combined with GALR2 antagonist M871 3 nmol 2 hours before the measures. 
The general schema of the experimental design is shown in Fig.1. 
mRNA Expression of Galanin receptors, C-Fos and Rab5 genes in the 
striatum in voluntary ethanol consumption 
Groups of rats from the two-bottle choice paradigm were killed by decapitation 2 
hours after a single i.c.v. administration of GAL(1-15) 3nmol or vehicle. The rats 
had free access to ethanol and water until the moment of sacrifice. The corpus 
striatum was manually dissected, including both the dorsal and ventral areas 
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from 2.2 mm anterior to bregma to 1.8 mm to bregma (Paxinos, 1986) and 
frozen on solid CO2 until mRNA expression analysis.  
RNA isolation and quantitative real-time PCR analysis 
The procedure to perform RNA isolation and RT-PCR was described previously 
(Millon et al., 2015). Total RNA was isolated from the striatum using RNeasy 
Lipid Tissue Kit (Qiagen, Hilden, Germany). cDNA was obtained using a 
Reverse Transcriptase Core Kit (Eurogentec, Seraing, Belgium). These steps 
were performed according to the manufacture’s instructions. 
All PCR were conducted in triplicate using Power SYBR Green PCR Master Mix 
(Applied Biosystems, Foster City, USA) in 7500 RT-PCR system (Applied 
Biosystems, Foster City, USA). The primers sequences used in this study are:  
GAPDH-Forward: 5 ́-GCTCTCTGCTCCTCCCTGTTC; GAPDH-Reverse:5 ́-
GAGGCTGGCACTGCACAA;  
GALR1-Forward: 5 ́-AAAACTGGACAAAACTTAGCC; GALR1-Reverse: 5 ́-
GGATACCTTTGTCTTTGCTC;  




RAB5-Fordward: 5’-AAAAGAGCTGTTGACTTCC;  RAB5-Reverse: 5’-
AGGTCTACTCCTCTTCCTC. The data were analyzed using the comparative 
Ct method and normalized to measures of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) mRNA 
 
Alcohol dehydrogenase assay 
The activity of hepatic cytosolic alcohol dehydrogenase (ADH) in the rats from 
the two-bottle choice test was analysed. ADH activity has a good correlation 
with ethanol elimination rates in vivo (Lumeng et al., 1979) and chronic ethanol 
administration causes an increase in ADH activity (Buris et al., 1985). 
The livers were removed 2 hours after i.c.v. injections and frozen in solid CO2 
until use. Determination of ADH activity was perform in homegenated of liver 
tissue in TrisHCl solution (10mM pH8,8 0.5 mM dithiothreitol) centrifuged at 
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12.000g during 10 min. ADH activity  was evaluated using a microassay 
adapted to Cobas Mira  according to Shephard and colleges (Shephard et al., 
1987). Briefly, 300 μL of NAD solution (2.9 mM in 0.1M Glycine/NaOH  pH10) 
was added to 30 μL of sample. The first optical reading was recorded before the 
addition of 20 μL of 17 mM ethanol and then the rate of change in absorption of 
the NADH chromogen is monitored at 340 nm over time on the Cobas Mira at 
37 oC. One activity unit was defined as the reduction of 1 mol NAD to 
NADH/min at 37 oC. 
Locomotor activity experiments 
In this experiment the effects of GAL(1-15) (3nmol) on ethanol-reduced 
locomotion (1.75 g/Kg; intraperitoneal (i.p.)) (Vallof et al., 2016) were 
investigated. Locomotor activity was registered in the rat open field (100 x 100 x 
50cm) where animals were individually placed and allowed to freely explore. 
Their behaviour was recorded over 30 min period by ceiling-mounted video 
camara and locomotor activity was analyzed using the video-tracking software 
EthovisionXT. After each trial, all surfaces were cleaned with a paper towel and 
70% ethanol solution. For the locomotor activity, the total distance travelled 
(cm) and mean speed (cm/s) were recorded. Groups of rats were administrated 
via i.c.v. with GAL(1-15) or vehicle 20 min before the test and the i.p. ethanol 
(1.75 g/Kg) or saline administration was 5 min prior the test. 
 
Expression of mRNA of GALR1 and GALR2 after acute administration of 
ethanol  
Groups of naïve rats were injected i.p. with ethanol 4g/Kg (50%v/v 10mL/Kg) 
(Bilbao et al., 2016), dissolved in sterile saline 0.9 % (w/v), and 0, 2 and 4 hours 
after injection the brains were collected after a rapid decapitation. The corpus 
striatum was manually dissected, including both the dorsal and ventral areas 
from 2.2 mm anterior to bregma to 1.8 mm posterior to bregma (Paxinos, 1986) 
and frozen immediately on solid CO2 until use. The procedure to perform RNA 
isolation and RT-PCR was described previously. 
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Statistical Analysis 
Data are presented as the means ± standard error of the mean and sample 
numbers (n) are indicated in figure legends. All data were analyzed using 
GraphPad PRISM 4.0 (GraphPad Software). For comparing two experimental 
conditions, student’s unpaired t-test statistical analyses were performed. 
Otherwise, one-way analyses of variance (ANOVAs) or two-way ANOVAs 
followed by Fisher’s LSD comparison post-tests were performed. Differences 
were considered significant at p < 0.05 (*p < 0.05, ** p < 0.01, *** p < 0.001). 
 
RESULTS 
Liver ADH activity in voluntary ethanol consumption  
Voluntary ethanol intake through two-bottle choice test protocol induced a 
significant increased in the ADH activity compared with baseline group 
(t11=3.281 p<0.01), confirming the validity of our model (Table 1). 
 
GAL(1-15) induced a decrease of ethanol intake and alcohol preference in 
the two-bottle choice paradigm 
GAL(1-15) at 3 nmol significantly decreased the ethanol intake at 2 hours (one-
way ANOVA, F2,30=3.54 p<0.05, Fisher’s LSD post-hoc test: p<0.05; Fig. 2a), 
14 hours (one-way ANOVA, F2,30=3.44 p<0.05, Fisher’s LSD post-hoc test: 
p<0.05; Fig.2b) and 24 hours (one-way ANOVA, F2,29=3.59 p<0.05, Fisher’s 
LSD post-hoc test: p<0.05; Fig. 2c) after its administration. GAL(1-15) at the 
dose of 1 nmol lacked effect on ethanol intake in all the time-points analysed. 
Moreover, 2 hours after i.c.v. GAL(1-15) 3 nmol a significantly decreased by 
90% in preference was observed (one-way ANOVA, F2,31=3.46 p<0.05, 
Fisher’s LSD post-hoc test: p<0.05; Fig. 2g). This effect was maintained 24 
hours (one-way ANOVA, F2,31=3.57 p<0.05, Fisher’s LSD post-hoc test: 
p<0.05; Fig. 2i). The dose of GAL(1-15) 1nmol lacks again of effects in 
preference. 
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In the water (Fig. 2d,e,f) and food intake (Fig. 2j,k,l), no differences were found 
at any time-point after GAL(1-15) i.c.v. administration at any dose. 
These results indicate that GAL(1-15) evokes a strong decrease in voluntary 
ethanol intake and preference in rats. 
 
Comparison between GAL and GAL(1-15) in the two-bottle choice 
paradigm 
In the ethanol intake, the overall one-way ANOVA revealed a significant 
difference between the N-terminal fragment GAL(1-15) and GAL at 2, 14 and 24 
hours after treatments. Two hours after the injection, GAL(1-15) significantly 
reduced the ethanol intake compared to GAL (one-way ANOVA, F2,31=4.208 
p<0.05, Fisher’s LSD post-hoc test: p<0.01; Fig. 3a). The same pattern of 
response was observed at the others times, GAL(1-15) significantly decreased 
the ethanol intake versus GAL groups 14 (one-way ANOVA, F2,30=3.97 p<0.05, 
Fisher’s LSD post-hoc test: p<0.05; Fig. 3b) and 24 hours (one-way ANOVA, 
F2,30=2.53 p<0.05, Fisher’s LSD post-hoc test: p<0.05; Fig. 3c) after i.c.v. 
injection. 
On the preference, the difference between GAL and GAL(1-15) was observed 
again. GAL(1-15) decreased the preference compared with GAL 2 hours after 
its administration (one-way ANOVA, F2,30=3.55 p<0.05, Fisher’s LSD post-hoc 
test: p<0.05; Fig. 3g), effect that was maintained 24 hours later (one-way 
ANOVA, F2,32=3.43 p<0.05, Fisher’s LSD post-hoc test: p<0.05; Fig. 3i).  
GAL lacks effect on the ethanol intake and preference compared to the vehicle 
at any time point (Fig. 3). 
No differences were found between GAL and the fragment GAL(1-15) in water 
intake (Fig. 3d, e, f) and food intake (Fig. 3j, k, l). 
 
GALR2 Antagonist M871 Blocked GAL(1-15)-mediated effects in the two-
bottle choice paradigm 
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In the two-bottle choice test, GALR2 antagonist M871 significantly blocked the 
decreased in the ethanol intake (one-way ANOVA, F2,34=3.72 p<0.05, Fisher’s 
LSD post-hoc test: p<0.05; Fig. 4a) induced by GAL(1-15) 2 hours after its 
administration.  
In the preference the same type of change was observed. Thus, GALR2 
participates in GAL(1-15)-mediated effect, since the GALR2 antagonist M871 
significantly blocked the decreased on preference induced by GAL(1-15) (one-
way ANOVA, F2,32=3.39 p<0.05, Fisher’s LSD post-hoc test: p<0.05; Fig. 4c). 
The GALR2 antagonist M871 alone at the dose of 3 nmol lacked effects on 
ethanol intake (0.13±0.06 g/Kg) and preference (12.65±8.23 %). 
Neither water (Fig. 4b) nor food intake (Fig. 4d) were modified by M871 (water 
intake: 8.26±2.00 g/Kg; food intake: 6.67±0.95 g) or GAL(1-15)+M871 2 hours 
after injection. 
 
GAL(1-15) effects mRNA Expression of Galanin receptors, C-Fos and 
Rab5 genes in the striatum in voluntary ethanol consumption 
As shown in Fig. 5, GAL(1-15) at dose of 3 nmol produced a significant increase 
in the mRNA levels of C-Fos (t8=5.488 p<0.001;Fig. 5a) and Rab5 (t6=4.148 
p<0.01;Fig. 5b) in the two-bottle choice test 2 hour after its administration.  
The administration of GAL(1-15) also modified the GALR1 and GALR2 
receptors expression in striatum, producing a significant decreased of GALR1 
mRNA levels (t10=2.341 p<0.05; Fig. 5c) and a slight reduction in GALR2 
expression (t10=1.360 p=0.101; Fig. 5d), suggesting the involvement of both 
receptors in the effects of GAL(1-15). 
 
Effects of GAL(1-15) on ethanol-reduced locomotion 
As previously described, the i.p. administration of ethanol 1.75 g/kg reduced the 
distance travelled (one-way ANOVA, F1,25=62.2 p<0.001) and the mean speed 
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(one-way ANOVA, F1,25=62.2 p<0.001) five minutes after its administration 
(Fig. 6). 
The effect of GAL(1-15) 3nmol on locomotion (distance travelled and mean 
speed), was dependent on i.p. ethanol (distance travelled: two-way ANOVA for 
alcohol/i.c.v.-treatment interaction F1,25=7.19 p<0.01; mean speed two-way 
ANOVA for alcohol/i.c.v.-treatment interaction F1,25=7.19 p<0.01) (Fig. 6). 
Thus, in rats following i.p. administration of ethanol, GAL(1-15) decreased the 
distance travelled (Fisher’s LSD post-hoc test: p<0.001; Fig. 6a), whereas no 
such effects were observed in rats with systemic administration of saline 
(Fisher’s LSD post-hoc test: p=0.71; Fig. 6a). Similar to the distance travelled, 
GAL(1-15) decreased the mean speed only in the rats systemically treated with 
ethanol (Fisher’s LSD post-hoc test: p<0.001; Fig. 6b). 
 
GALR1 and GALR2 expression in the striatum after the acute 
administration of ethanol 
To determine whether ethanol influenced GALR1 and GALR2 expression in the 
striatum, we evaluated the effects of the acute ethanol administration on mRNA 
GALR1 and GALR2 levels in the striatum at 2 and 4 hours. 
As shown in Figure 7, a single ethanol injection (4g/Kg i.p.) lacked effect in the 
GALR1 expression in the striatum 2 and 4 hours after administration (one-way 
ANOVA, F2,14=1.19 p=0.24)  
No effects were observed also in the GALR2 mRNA levels in any of the time-
points (one-way ANOVA, F2,14=1.15 p=0.34). 
 
DISCUSSION  
In the current study, we described for the first time that GAL(1-15), via central 
mechanisms, induces a strong reduction in preference and ethanol 
consumption in rats. These effects were significantly different than GAL, 
showing a differential role of GAL compared with GAL(1-15) in alcohol 
consumption behaviour. GALR2 was involved in these effects, since the specific 
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GALR2 antagonist M871 blocked GAL(1-15) mediated actions in preference 
and ethanol intake. Importantly, the mechanism of this action involves changes 
in GAL receptors expression and also in immediate-early gene C-Fos and 
receptors-internalization-related gene Rab5 in striatum, area rich in GAL-
fragment binding sites (Hedlund et al., 1992) and critical for the rewarding and 
motivational effects of drugs of abuse (Koob, 1992). The relevance of the 
striatum as a target for GAL(1-15) was also supported by the effect of GAL(1-
15) on the locomotor activity of rats after ethanol administration. 
GAL(1-15) at the dose of 3 nmol induced a strong reduction in preference and 
ethanol consumption in the two-bottle choice test at 2 hours, effect that was 
maintained at 24 hours. Given that this alcohol two-bottle-choice drinking 
paradigm induces voluntary intake of high amounts of alcohol (Simms et al., 
2008), the present data may suggest that GAL(1-15) could be used as a 
pharmacological agent to treat AUD in humans.  
Although emotional states as anxiety are relevant variables to modulate 
alcohol-taking behaviour, increasing alcohol consumption and preference 
(Chappell et al., 2013), and GAL(1-15) increases anxiety- and depressive-like 
behaviours in rats (Millon et al., 2015; Millon et al., 2017), the fact that GAL(1-
15) induced a reduction in alcohol intake and preference suggest that the 
mechanism involved is independent of the effect of GAL(1-15) in the emotional 
states. 
In addition, a tentative explanation for the reduced alcohol intake induced by 
central GAL(1-15) administration, is that GAL(1-15) by itself may induce 
aversion rather than attenuate the rewarding properties of alcohol. However, 
the selected doses of GAL(1-15) lack effect on water and food intake 
suggesting that the reduced alcohol intake is not driven by aversion to alcohol. 
Since GAL(1-15) did not modify the food intake in rats that had been chronically 
consuming ethanol, it can also be suggested that in our model, the rats were 
not consuming ethanol just for its calories (Lewis et al., 2004).  
Furthermore, the effects of GAL(1-15) in the two-bottle choice test were 
significantly different than the corresponding effects induced by GAL. In our 
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model GAL 3 nmol lacked effect with respect to vehicle group in all the 
parameters studied. In previous studies, GAL microinjected into the third 
ventricle increased the 7% ethanol intake in the two-bottle choice test (Lewis et 
al., 2004), and this increase was stronger during the light phase, when the 
animals are inactive and normally drink very little (Lewis et al., 2004). The 
different results found in the present work could be explained in the differences 
of the percentage of ethanol and the light-dark cycle used, since we used the 
choice between 10% ethanol versus water, and the percentage of ethanol 
solution could affect the result of the test (Leeman et al., 2010; Tarragon et al., 
2012). Moreover, we performed the measures in the dark period, when the rats 
are more active, while the ethanol intake produced by GAL was stronger in the 
light period (Lewis et al., 2004). 
However, since GAL(1-15) reduced the preference and ethanol consumption, 
opposite effect found by GAL by other authors, our results validate and extend 
the view of a specific role of GAL(1-15) in ethanol intake. 
We have previously described a different action of GAL and GAL(1-15) in 
behaviour functions (Millon et al., 2017). GAL(1-15) induces depression-related 
and anxiogenic-like effects in rats, and these effects were significantly stronger 
than the one induced by GAL (Millon et al., 2015). GAL(1-15) is also able to 
enhance the antidepressant effects induced by the 5HT1A agonist 8-OH-DPAT 
in the Forced Swimming Test, an effect that was again significantly stronger 
than the one induced by GAL (Millon et al., 2016). The different action between 
GAL and GAL(1-15) was observed not only in behavioural functions, but also in 
central cardiovascular regulation (Diaz-Cabiale et al., 2005; Diaz-Cabiale et al., 
2010). Our results in the ethanol intake confirm a unique action of GAL(1-15) in 
brain communication.  
The mechanism that explained the differences between the GAL, and GAL(1-
15) is that this N-terminal GAL fragment preferring site is the result of formation 
of GALR1/GALR2 heteromers highly specific for GAL fragments (Fuxe et al., 
2008; Fuxe et al., 2012; Millon et al., 2015). The fact that GALR2 antagonist 
M871 blocked the reduction in preference and ethanol intake induced by 
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GAL(1-15), confirms that GAL(1-15) acts through heterodimer GALR1/GALR2 
to reduce the preference and ethanol consumption.  
The GAL receptors involved in alcoholism are not well characterized; however, 
several studies suggested that GALR3 was involved in alcohol consumption 
(Belfer et al., 2007; Ash et al., 2011; Ash et al., 2014; Scheller et al., 2017). 
Since GALR3 is mainly restricted to the hypothalamus and pituitary (Smith et al., 
1998; Waters et al., 2000) it has been proposed that these areas are crucial for 
this effect. Our results demonstrate the importance of GALR1 and GALR2 in the 
reduction of preference and ethanol intake induced by GAL(1-15) and suggest 
that the striatum, a key region in the reward effects of drugs (Koob, 1992), is 
involved in GAL(1-15)-mediated effects. In our voluntary ethanol consumption 
model, GAL(1-15) induced a significant increase of C-Fos mRNA and Rab5 
expression in the striatum suggesting an enhancement of neuronal activation 
and receptor internalization in this area (Borroto-Escuela et al., 2012). Moreover, 
in these animals, we observed after GAL(1-15) injection a significant reduction 
of GALR1 expression and a slight decrease in GALR2 mRNA in the striatum 
suggesting that both striatal receptors participated in the GAL(1-15)-mediated 
effects on the voluntary ethanol intake in this nucleus. Interestingly, the 
evidence that acute ethanol injections in naïve animals lacks of effect in GALR1 
and GALR2 expression in the striatum, indicates that ethanol per se do not 
influence GALR expression and confirm that the effects at GALR level in our 
model were induced by GAL(1-15). 
The relevance of the striatum as a target for GAL(1-15) was supported by the 
the ability of GAL(1-15) to enhance the suppression of locomotor activity 
induced by ethanol. Ethanol suppression of locomotor activity following ethanol 
i.p. injection is a well-known behavioural effect mainly mediated by the 
dopaminergic system, involving the striatum. Accordingly, it has been 
demonstrated that this effect is notably reduced when the dopaminergic system 
is lesioned using 6-OHDA, producing strong dopamine depletion in the striatum 
(Breese et al., 1984). Our results suggest, that the potentiation of the 
hypolocomotion induced by GAL(1-15) in rats treated with alcohol, may require 
the modulation of the dopaminergic system by GAL(1-15), probably involving 
the striatum because it is a crucial target of the dopaminergic projections. 
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Although previously, the increase in the ethanol intake of GAL was related 
directly with several areas within the hypothalamus (Leibowitz et al., 2003; 
Rada et al., 2004; Schneider et al., 2007), the current work suggests that 
GAL(1-15) act through the striatum, an area which has specifics binding sites 
for GAL(1-15) (Hedlund et al., 1992). The involvement of the striatum in GAL(1-
15)-mediated action would explain the different action between GAL and 
GAL(1-15) in ethanol intake. 
Further studies are needed to describe the neurochemical pathways involved in 
the reduction of ethanol consumption by GAL(1-15); however the dopamine 
should be consider a target neurotransmitter in this effect. Supporting this 
hypothesis, GAL reduces behavioural response following treatment with several 
addictive substances such as morphine or amphetamines mainly modulating 
dopaminergic neurotransmission (Tsuda et al., 1998; Pierce et al., 2006) and 
dopamine transmission plays a crucial role in the motor effects of alcohol in the 
striatum (Brabant et al., 2014). 
In conclusion, our results indicate that the N-terminal fragment GAL(1-15) 
induces a strong reduction in preference and ethanol consumption in rats 
probably with the involvement of the striatum, a key region in the reward effects 
of drugs. These results may give the basis for the development of novel 
therapeutics strategies using GAL(1-15) analogues for the treatment of AUD in 
humans. 
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Table 1. Liver ADH activity of animals of two-bottle choice paradigm 
ADH Activity 
Treatment Baseline Veh/EtOH 




Effects of voluntary ethanol intake in animals of two-bottle choice test over 
the liver ADH activity. Cerebrospinal fluid-injected rats were used as the 
vehicle group and naïve rats were used as baseline group. Data are mean ± 
SEM (n=6-7 animals per group). **p<0.01 versus baseline group according 
to student’s t-test. 
 
Figure Legends 
Figure 1. Experimental design of voluntary ethanol intake.  
Figure 2. Dose-response curve of Galanin (1-15) [GAL15] in the two-bottle 
choice paradigm with 10% ethanol (EtOH) concentration in rats. GAL15 (at 1 or 
3 nmol/rat) (n=7-9 animals per group) was administrated i.c.v. 2, 14 and 24 
hours before the measures. Cerebrospinal fluid-injected rats were used as the 
vehicle group (n=15-18 animals). Vertical bars represent mean ± SEM of EtOH 
intake (g/Kg; a, b, c) , water intake (g/kg; d, e, f), preference EtOH (%; g, h, i) 
and Food Intake (g; j, k, l) during the differents periods.(a) *p<0.05 versus rest 
of the groups (rest of graphs) *p<0.05 versus vehicle group according to one-
way ANOVA followed by Fisher’s LSD test. 
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Figure 3. Effect of administration of Galanin (GAL) and Galanin (1-15) [GAL15] 
in the two-bottle choice paradigm with 10% ethanol (EtOH) concentration in rats. 
GAL (3 nmol/rat) and GAL15 (3 nmol/rat) (n=7-13 animals per group) were 
administrated i.c.v. 2, 14 and 24 hours before the measures. Cerebrospinal 
fluid-injected rats were used as the vehicle group (n=10-15 animals). Vertical 
bars represent mean ± SEM of EtOH intake (g/Kg; a, b, c) , water intake (g/kg; d, 
e, f), preference EtOH (%; g, h, i) and food Intake (g; j, k, l) during the differents 
periods. (a)*p<0.05 versus vehicle and **p<0.01 versus GAL15 3 nmol group 
(rest of graphs)*p<0.05 versus rest of the groups according to one-way ANOVA 
followed by Fisher’s LSD test. 
Figure 4. Effects of co-administration of GALR2 receptor antagonist M871 (3 
nmol/rat) and Galanin (1-15) [GAL15] (n=7-9 animals per group) in the two-
bottle choice paradigm with 10% ethanol (EtOH) concentration in rats. 
Treatments were injected i.c.v. 2 hours before the measures. Cerebrospinal 
fluid-injected rats were used as the vehicle group (n=18-20 animals). Vertical 
bars represent mean ± SEM of (a) EtOH intake (g/Kg), (b) water intake (g/kg), 
(c) preference EtOH (%) and (d) food Intake (g) during the differents periods. 
*p<0.05 versus rest of the groups according to one-way ANOVA followed by 
Fisher’s LSD test. 
Figure 5. Effects of Galanin (1-15) [GAL15] in the striatum mRNA expression of 
C-Fos (a), Rab5 (b), GALR1 (c) and GALR2 (d) in the two-bottle choice 
paradigm exposed rats. GAL15 was injected i.c.v. 2 hours before the measures. 
Cerebrospinal fluid-injected rats were used as the vehicle group. Vertical bars 
represent mean ± SEM (n= 5-6 animals per group). *p<0.05; **p<0.01; ***p<0.001 
versus Veh/EtOH group according to student’s t-test. 
Figure 6. Effects of Galanin 1-15 [GAL15] in ethanol-induced locomotors 
modification in rats. GAL15 (3nmol; i.c.v.) was injected 20 min before the test 
and acute injection of ethanol (1.75 g/Kg; I.P.) was administrated 5 min before 
the test. Data represents mean ± SEM (n=6-8 animals per groups) of total 
distance travelled (a) and mean speed (b) in open field during the 5 min test 
period. ***p<0.001 according to two-way ANOVA followed by Fisher’s LSD test. 
Figure 7. Effects of ethanol administration on GALR1 and GALR2 expression in 
the striatum. Effects of acute i.p. administration of EtOH (4 g/Kg) on GALR1 (a) 
and GALR2 (b) mRNA expression in striatum were measured at 0, 2 and 4 
hours after injection. Data are mean ± SEM (n= 4-8 animals per group). No 
significant differences were found by one-way ANOVA. 












Millón et al., 2017                                                                       Addiction Biology 
 27 
 
